CIMA Labs reconsiders
This article was originally published in The Tan Sheet
Executive Summary
CIMA Labs says "there is a reasonable likelihood" that an unsolicited acquisition offer from Rx drug maker Cephalon "would reasonably be expected to result in a superior proposal" to an already-agreed upon stock-swap transaction with aaiPharma, according to a Sept. 19 release. Cephalon sent a letter to CIMA's board on Sept. 10 asking them to reconsider their decision to reject the Rx firm's proposal (1"The Tan Sheet" Sept. 15, 2003, p. 7). aaiPharma remains "committed" to completing the merger with CIMA, the company said in a statement...
You may also be interested in...
Cephalon hires FDA free agent
Victor Raczkowski, former director for FDA's Office of Drug Safety, joins Cephalon as VP-regulatory affairs. Cephalon is embattled in a bidding war with aaiPharma to acquire CIMA Labs (1"The Tan Sheet" Sept. 22, 2003, In Brief). Raczkowski is the second ODS director to leave the agency for an industry position; Peter Honig joined Merck as VP-risk management in February 2002 (2"The Tan Sheet" Jan. 21, 2002, p. 23)...
Cephalon Approaches CIMA Labs To Resuscitate Merger Talks
Cephalon is attempting to restart talks with CIMA Laboratories regarding a potential acquisition of the company with a Sept. 10 letter sent to CIMA's board
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”